These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 16487187)

  • 1. Protective effect of prophylaxis on inhibitor development in children with haemophilia A: more convincing studies are required.
    Calvez T; Laurian Y
    Br J Haematol; 2006 Mar; 132(6):798-800; author reply 800-1. PubMed ID: 16487187
    [No Abstract]   [Full Text] [Related]  

  • 2. A case report of a premature infant with haemophilia A and factor VIII inhibitor.
    Cartledge P; Deakin K; McKecknie L; Richards M
    Haemophilia; 2011 Jul; 17(4):711-2. PubMed ID: 21371187
    [No Abstract]   [Full Text] [Related]  

  • 3. High titre inhibitor to factor VIII in a haemophilia carrier.
    Marino R; Malcangi G; Margaglione M; Ettorre CP
    Haemophilia; 2014 May; 20(3):e237-40. PubMed ID: 24731130
    [No Abstract]   [Full Text] [Related]  

  • 4. Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A.
    Franchini M; Girelli D; Olivieri O; Castaman G; Lippi G; Poli G; Salvagno GL; Tagariello G; Giuffrida A; de Gironcoli M; Morfini M; Berntorp E; Gandini G
    Haemophilia; 2006 Jul; 12(4):448-51. PubMed ID: 16834751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of inhibitors in haemophilia. Ongoing epidemiological study.
    Serban M; Mihailov D; Pop L; Ionita H; Ursu E; Talpos-Niculescu S; Ritli L; Baghiu D; Uscatescu V; Petrovanu C; Stancu P; Savescu D; Cucuianu A; Schramm W
    Hamostaseologie; 2011 Nov; 31 Suppl 1():S20-3. PubMed ID: 22057218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orthotopic liver transplantation in a patient with severe haemophilia A and a high-titre factor VIII inhibitor from an antithrombin-deficient cadaveric donor.
    Gregg R; Lester W; Bramhall S; Wilde J
    Haemophilia; 2013 Mar; 19(2):e96-7. PubMed ID: 23419109
    [No Abstract]   [Full Text] [Related]  

  • 7. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates.
    Tagariello G; Zanotto D; Radossi P; Sartori R; Belvini D; Salviato R
    Am J Hematol; 2007 Jun; 82(6):460-2. PubMed ID: 17211843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allergenic vaccines administration and inhibitor development in haemophilia.
    Bermejo N; Martín Aguilera C; Carnicero F; Bergua J
    Haemophilia; 2012 Sep; 18(5):e392-3. PubMed ID: 22672147
    [No Abstract]   [Full Text] [Related]  

  • 9. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study.
    Santagostino E; Mancuso ME; Rocino A; Mancuso G; Mazzucconi MG; Tagliaferri A; Messina M; Mannucci PM
    Br J Haematol; 2005 Aug; 130(3):422-7. PubMed ID: 16042693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The correlation between gene mutations and inhibitor development in patients with haemophilia A in southern Iran.
    Haghpanah S; Sahraiian M; Afrasiabi A; Enayati S; Peyvandi F; Karimi M
    Haemophilia; 2011 Sep; 17(5):820-1. PubMed ID: 21371201
    [No Abstract]   [Full Text] [Related]  

  • 11. The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters.
    Kessler CM; Iorio A
    Haemophilia; 2013 May; 19(3):351-4. PubMed ID: 23577743
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibitors in mild/moderate haemophilia A: an update.
    Franchini M; Salvagno GL; Lippi G
    Thromb Haemost; 2006 Aug; 96(2):113-8. PubMed ID: 16894451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitor development, immune tolerance and prophylaxis in haemophilia A--the need for an evidence-based approach.
    Mannucci PM; Abshire T; Dimichele D; Santagostino E; Blanchette V
    Haemophilia; 2006 Jul; 12(4):429-34. PubMed ID: 16834746
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and efficacy of recombinant activated factor VII for long-term secondary prophylaxis in a haemophilia boy with high-titre inhibitors.
    Chuansumrit A; Sirachainan N; Panuwannakorn M; Wongwerawattanakoon P; Kadegasem P; Choeyprasert W; Sasanakul W
    Haemophilia; 2013 May; 19(3):e182-3. PubMed ID: 23600908
    [No Abstract]   [Full Text] [Related]  

  • 15. A child with acquired haemophilia.
    Somaratne PD; Jansan J; Senanayake HM; Ratnamalala V; Jayathilake MM; Thirumavalavan K
    Ceylon Med J; 2014 Jun; 59(2):66-7. PubMed ID: 24977427
    [No Abstract]   [Full Text] [Related]  

  • 16. [A cross-sectional survey of coagulation factor VIII inhibitor in children with hemophilia A].
    Wei Q; Li G; Tang L; Chen Z; Zhen Y; Wu X; Zhang N; Zhang J; Yu G; Wu R
    Zhonghua Er Ke Za Zhi; 2014 Feb; 52(2):99-102. PubMed ID: 24739719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haemophilia care in children--benefits of early prophylaxis for inhibitor prevention.
    Mancuso ME; Graca L; Auerswald G; Santagostino E
    Haemophilia; 2009 Jan; 15 Suppl 1():8-14. PubMed ID: 19125935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Laboratory monitoring of efficiency of different approaches to the therapy of patients with inhibitor form of haemophilia A].
    Nabieva MI
    Lik Sprava; 2009; (1-2):59-61. PubMed ID: 19953993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haemophilic arthropathy in haemophilia patients with inhibitors: new perspectives.
    Rodriguez-Merchan EC
    Haemophilia; 2003 Sep; 9(5):547-8. PubMed ID: 14511292
    [No Abstract]   [Full Text] [Related]  

  • 20. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia.
    Astermark J
    Haemophilia; 2006 Jul; 12 Suppl 3():52-60. PubMed ID: 16683997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.